

Breast cancer remains a significant health concern

References

1. Bray F, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 2024 Apr 4. doi: 10.3322/caac.21834.
2. American Cancer Society. Breast Cancer Facts & Figures 2024-2025. <https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/breast-cancer-facts-and-figures/2024/breast-cancer-facts-and-figures-2024.pdf> [Access Feb 2025].
3. Ahn S, et al. HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation. *J Pathol Transl Med*. 2020;54(1):34-44.
4. Bethune GC, et al. Well-differentiated invasive breast cancers with equivocal HER 2 immunohistochemistry: what is the yield of routine reflex in-situ hybridization testing? *Histopathology*. 2017;70:966–74. doi: 10.1111/his.13160.
5. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. *J Clin Oncol* 2007; 25: 118-45.
6. Liu ZH, Wang K, Lin DY, et al. Impact of the updated 2018 ASCO/ CAP guidelines on HER2 FISH testing in invasive breast cancer: a retrospective study of HER2 FISH results of 2233 cases. *Breast Cancer Res Treat* 2019; 175: 51-7.
7. Wolff AC, Hammond MEH, Allison KH, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical practice guideline focused update. *J Clin Oncol* 2018;36:2105-22.
8. Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. *N Engl J Med* 2022;387:9-20.
9. Sajjadi E, et al. Improving HER2 testing reproducibility in HER2-low breast cancer. *Cancer Drug Resist*. 2022;5(4):882-888.
10. The 2024 ASCO Annual Meeting (May 31 – June 4, 2024), Abstract e13023.
11. Poster presented at the San Antonio Breast Cancer Symposium (SABCS) 2024, San Antonio, Texas, US, December 10-13, 2024.